Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Attralus Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This active matter is being handled by 1 distinct examiner within 1 distinct art unit. This focused prosecution footprint indicates that the company's current intellectual property efforts are concentrated on a specific technical advancement within the biotechnology sector. The presence of only 1 distinct art unit suggests that the subject matter of the filing is highly specialized and does not currently span multiple technical jurisdictions at the patent office. This allows for a concentrated legal strategy that targets the specific expertise of the assigned unit.
OLGA N CHERNYSHEV is identified as the busiest examiner, managing 1 pending office action. As the sole examiner currently reviewing the company's applications, the progress of the portfolio is entirely dependent on the individual examination style and procedural requirements of this official. For practitioners, this concentration allows for a highly tailored response strategy that addresses the specific feedback of this examiner. With 1 pending office action in the Biotechnology & Pharmaceuticals area, the company's immediate prosecution success is tied to the resolution of this single active case, allowing for a dedicated focus on this specific examination without the need to manage multiple examiner relationships.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18289032 | PEPTIDE-FC FUSIONS FOR TREATING AMYLOID DISORDERS | CHERNYSHEV, OLGA N | — |
| Art Unit | Apps |
|---|---|
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18289032 | PEPTIDE-FC FUSIONS FOR TREATING AMYLOID DISORDERS | CHERNYSHEV, OLGA N | 1675 | §112 | Final Rejection | — | Pending | Oct 31, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAttralus Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Olga N Chernyshev has the most, with 1 of Attralus Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.